Suppr超能文献

载脂蛋白 E2 突变谱及阿尔茨海默病中新型功能验证突变:来自 PUMCH 痴呆队列的数据。

PSEN2 Mutation Spectrum and Novel Functionally Validated Mutations in Alzheimer's Disease: Data from PUMCH Dementia Cohort.

机构信息

Neurology Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Institute of Basic Medical Sciences, Peking Union Medical College, Beijing, China.

出版信息

J Alzheimers Dis. 2022;87(4):1549-1556. doi: 10.3233/JAD-220194.

Abstract

BACKGROUND

The established causative mutations in the APP, PSEN1, and PSEN2 can explain less than 1%,Alzheimer's disease (AD) patients. Of the identified variants, the PSEN2 mutations are even less common.

OBJECTIVE

With the genetic study from the dementia cohort of Peking Union Medical College Hospital (PUMCH), we aim to illustrate the PSEN2 mutation spectrum and novel functionally validated mutations in Chinese AD patients.

METHODS

702 AD participants, aged 30-85, were identified in PUMCH dementia cohort. They all received history inquiry, physical examination, biochemical test, cognitive evaluation, brain CT/MRI, and next-generation DNA sequencing. Functional analysis was achieved by transfection of the HEK293 cells with plasmids harboring the wild-type PSEN2 or candidate mutations.

RESULTS

Nine PSEN2 rare variants were found, including two reported (M239T, R62C) and seven novel variants (N141S, I368F, L396I, G117X, I146T, S147N, H220Y). The HEK293 cells transfected with the PSEN2 N141S, M239T, I368F plasmids showed higher Aβ42 and Aβ42/Aβ40 levels relative to the wild-type PSEN2. The PSEN2 L396I, G117X, S147N, H220Y, and R62C did not alter Aβ42, Aβ40 levels, or Aβ42/Aβ40 ratio. 1.9%,(13/702) subjects harbored rare PSEN2 variants. 0.4%,(3/702) subjects carried pathogenic/likely pathogenic PSEN2 mutations. The three subjects with the functionally validated PSEN2 mutations were all familial early-onset AD patients. The common symptoms included amnesia and mental symptom. Additionally, the M239T mutation carrier presented with dressing apraxia, visuospatial agraphia, dyscalculia and visual mislocalization.

CONCLUSION

The PSEN2 N141S, M239T, and I368F are functionally validated mutations.

摘要

背景

在 APP、PSEN1 和 PSEN2 中已确定的致病突变只能解释不到 1%的阿尔茨海默病(AD)患者。在已确定的变异中,PSEN2 突变更为罕见。

目的

通过对北京协和医学院医院(PUMCH)痴呆队列的遗传研究,我们旨在阐明中国 AD 患者中 PSEN2 突变谱和新的功能验证突变。

方法

在 PUMCH 痴呆队列中,我们确定了 702 名年龄在 30-85 岁的 AD 参与者。他们都接受了病史询问、体检、生化检查、认知评估、脑 CT/MRI 和下一代 DNA 测序。通过转染携带野生型 PSEN2 或候选突变的质粒,实现了功能分析。

结果

发现了 9 种 PSEN2 罕见变异,包括 2 种已报道的变异(M239T、R62C)和 7 种新变异(N141S、I368F、L396I、G117X、I146T、S147N、H220Y)。与野生型 PSEN2 相比,转染 PSEN2 N141S、M239T、I368F 质粒的 HEK293 细胞显示出更高的 Aβ42 和 Aβ42/Aβ40 水平。PSEN2 L396I、G117X、S147N、H220Y 和 R62C 并未改变 Aβ42、Aβ40 水平或 Aβ42/Aβ40 比值。1.9%(13/702)的受试者携带罕见的 PSEN2 变异。0.4%(3/702)的受试者携带致病性/可能致病性 PSEN2 突变。经功能验证的 PSEN2 突变的 3 名受试者均为家族性早发性 AD 患者。共同的症状包括健忘和精神症状。此外,M239T 突变携带者还出现穿衣失用症、视空间失写症、计算障碍和视觉定位错误。

结论

PSEN2 N141S、M239T 和 I368F 是经功能验证的突变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f200/9277672/106cbc6378cd/jad-87-jad220194-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验